沙美特罗/福替卡松对中重度慢阻肺患者稳定期的疗效观察

目的探讨沙美特罗／福替卡松治疗中重度慢阻肺患者稳定期的临床疗效．方法将132例稳定期中重度慢阻肺患者分为两组，对照组患者66例采用氨茶碱治疗，观察组患者66例采用沙美特罗／福替卡松治疗，治疗时间为4周，采用圣·乔治呼吸疾病问卷评定患者治疗前后的生存质量，分析两组患者相关临床指标的改变情况、治疗效果、不良反应情况．结果两组患者治疗后的指标FEV1，FEV1／预计值，FEV1／FVC，6min步行距离均明显增加，而圣·乔治呼吸疾病问卷评分却明显下降；观察组指标FEV1，FEV1／预计值，FEV1／FVC，6min步行距离、总有效率均明显高于对照组；观察组圣·乔治呼吸疾病问卷评分明显低于对照组，差异具有统计学意义（P〈0．05）；观察组不良反应发生率低于对照组，差异不具有统计学意义（P〉0．05）．结论沙美特罗／福替卡松是治疗稳定期中重度慢阻肺的有效药物，可明显改善肺功能，提高治疗效果，并发症少，安全性高．

Curative Observation of Salmeterol/Fluticasone on Moderate or Severe COPD in Stable Stage

Objective To investigate the clinical effect of salmeterol/fluticasone in the treatment for patients with moderate or severe COPD in stable stage. Method 132 patients with moderate or severe COPD （chronic obstructive pulmonary diseases） in stable stage were divided into two groups. 66 patients in the control group were treated with aminophylline and the other 66 patients in the observation group were treated with salmeterol/ fluticasone. The course of treatment was 4 weeks. The quality of life was assessed by St. George＇ s respiratory questionnaire before and after treatment. Changes in clinical indices, curative effects and drug adverse reactions in patients in two groups were compared. Results After treatment, FEV1, FEV1/estimates, FEV1/FVC and 6- minute walk distance increased significantly, while St. George ＇ s respiratory questionnaire scores decreased significantly in two groups. FEV1, FEV1/estimates, FEV1/FVC ,6-minute walk distance, total effective rate in the observation group were significantly higher than those in the control group. St. George＇ s respiratory questionnaire score in the observation group was significantly lower than that in the control group, and the difference was statistically significant（ P 〈 0.05）. The incidence of adverse reactions in the observation group was lower than that in the control group, but the difference was not statistically significant （ P 〉 0.05 ）. Conclusion The therapy with salmeterol/fluticasone is an effective one in the treatment of moderate or severe COPD in stable stage, which can significantly improve the lung function, improve the therapeutic effect and can cause less complications and should be high safe.